Literature DB >> 28104789

A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles.

Amber L Southwell1, Niels H Skotte1,2, Erika B Villanueva1, Michael E Østergaard3, Xiaofeng Gu4, Holly B Kordasiewicz3, Chris Kay1, Daphne Cheung1, Yuanyun Xie1, Sabine Waltl1, Louisa Dal Cengio1, Hailey Findlay-Black1, Crystal N Doty1, Eugenia Petoukhov1, Diepiriye Iworima1, Ramy Slama1, Jolene Ooi5, Mahmoud A Pouladi5,6, X William Yang4, Eric E Swayze3, Punit P Seth3, Michael R Hayden1.   

Abstract

Huntington disease (HD) is a neurodegenerative disease caused by a mutation in the huntingtin (HTT) gene. HTT is a large protein, interacts with many partners and is involved in many cellular pathways, which are perturbed in HD. Therapies targeting HTT directly are likely to provide the most global benefit. Thus there is a need for preclinical models of HD recapitulating human HTT genetics. We previously generated a humanized mouse model of HD, Hu97/18, by intercrossing BACHD and YAC18 mice with knockout of the endogenous mouse HD homolog (Hdh). Hu97/18 mice recapitulate the genetics of HD, having two full-length, genomic human HTT transgenes heterozygous for the HD mutation and polymorphisms associated with HD in populations of Caucasian descent. We have now generated a companion model, Hu128/21, by intercrossing YAC128 and BAC21 mice on the Hdh-/- background. Hu128/21 mice have two full-length, genomic human HTT transgenes heterozygous for the HD mutation and polymorphisms associated with HD in populations of East Asian descent and in a minority of patients from other ethnic groups. Hu128/21 mice display a wide variety of HD-like phenotypes that are similar to YAC128 mice. Additionally, both transgenes in Hu128/21 mice match the human HTT exon 1 reference sequence. Conversely, the BACHD transgene carries a floxed, synthetic exon 1 sequence. Hu128/21 mice will be useful for investigations of human HTT that cannot be addressed in Hu97/18 mice, for developing therapies targeted to exon 1, and for preclinical screening of personalized HTT lowering therapies in HD patients of East Asian descent.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28104789     DOI: 10.1093/hmg/ddx021

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  9 in total

Review 1.  Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Authors:  Jana Miniarikova; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

2.  Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.

Authors:  Nicholas S Caron; Raul Banos; Amirah E Aly; Yuanyun Xie; Seunghyun Ko; Nalini Potluri; Christine Anderson; Hailey Findlay Black; Lisa M Anderson; Benjamin Gordon; Amber L Southwell; Michael R Hayden
Journal:  Neurobiol Dis       Date:  2022-02-07       Impact factor: 5.996

Review 3.  Current and Possible Future Therapeutic Options for Huntington's Disease.

Authors:  Mackenzie W Ferguson; Connor J Kennedy; Thulani H Palpagama; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  J Cent Nerv Syst Dis       Date:  2022-05-21

4.  Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.

Authors:  Nicholas S Caron; Amber L Southwell; Cynthia C Brouwers; Louisa Dal Cengio; Yuanyun Xie; Hailey Findlay Black; Lisa M Anderson; Seunghyun Ko; Xiang Zhu; Sander J van Deventer; Melvin M Evers; Pavlina Konstantinova; Michael R Hayden
Journal:  Nucleic Acids Res       Date:  2020-01-10       Impact factor: 16.971

5.  A novel and accurate full-length HTT mouse model for Huntington's disease.

Authors:  Sushila A Shenoy; Sushuang Zheng; Wencheng Liu; Yuanyi Dai; Yuanxiu Liu; Zhipeng Hou; Susumu Mori; Yi Tang; Jerry Cheng; Wenzhen Duan; Chenjian Li
Journal:  Elife       Date:  2022-01-13       Impact factor: 8.140

6.  Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.

Authors:  Faith Conroy; Rachael Miller; Julia F Alterman; Matthew R Hassler; Dimas Echeverria; Bruno M D C Godinho; Emily G Knox; Ellen Sapp; Jaquelyn Sousa; Ken Yamada; Farah Mahmood; Adel Boudi; Kimberly Kegel-Gleason; Marian DiFiglia; Neil Aronin; Anastasia Khvorova; Edith L Pfister
Journal:  Nat Commun       Date:  2022-10-03       Impact factor: 17.694

7.  A pathogenic proteolysis-resistant huntingtin isoform induced by an antisense oligonucleotide maintains huntingtin function.

Authors:  Hyeongju Kim; Sophie Lenoir; Angela Helfricht; Taeyang Jung; Zhana K Karneva; Yejin Lee; Wouter Beumer; Geert B van der Horst; Herma Anthonijsz; Levi Cm Buil; Frits van der Ham; Gerard J Platenburg; Pasi Purhonen; Hans Hebert; Sandrine Humbert; Frédéric Saudou; Pontus Klein; Ji-Joon Song
Journal:  JCI Insight       Date:  2022-09-08

8.  AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.

Authors:  Melvin M Evers; Jana Miniarikova; Stefan Juhas; Astrid Vallès; Bozena Bohuslavova; Jana Juhasova; Helena Kupcova Skalnikova; Petr Vodicka; Ivona Valekova; Cynthia Brouwers; Bas Blits; Jacek Lubelski; Hana Kovarova; Zdenka Ellederova; Sander J van Deventer; Harald Petry; Jan Motlik; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-06-25       Impact factor: 11.454

9.  Escins Isolated from Aesculus chinensis Bge. Promote the Autophagic Degradation of Mutant Huntingtin and Inhibit its Induced Apoptosis in HT22 cells.

Authors:  Yueshan Sun; Xueqin Jiang; Rong Pan; Xiaogang Zhou; Dalian Qin; Rui Xiong; Yiling Wang; Wenqiao Qiu; Anguo Wu; Jianming Wu
Journal:  Front Pharmacol       Date:  2020-02-25       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.